GREY:IPHAF - Post by User
Comment by
biodelatechon Aug 03, 2007 4:28am
166 Views
Post# 13195731
RE: nothing new
RE: nothing newthe race that matters more is 247 vs. tacrolimus.
I think 247 will beat tacro on side effects and at least match tacro´s efficacy.
of course tacro is only just another billion dollar drug with rising sale figures.
I think ISA should scrap 247 development and look for drugs with potential sales in the 5-10 billion dollar range.
anything below that is just a waste of time.